IBRO neuroscience reports · 2026
Therapeutic potential of edaravone and flurbiprofen in valproic acid-induced autism: Targeting oxidative stress and neuroinflammation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hejazi Anahita, Hajisoltani Razieh, Farbib Mitra, Sadr Hossein, Mehrabi Fatemeh, Baluchnejadmojarad Tourandokht, Mehrabi Soraya
Аннотация
BACKGROUND AND OBJECTIVES: Autism Spectrum Disorder (ASD) presents significant therapeutic challenges, with growing evidence implicating neuroinflammation and oxidative stress in its pathophysiology. This study aimed to investigate the protective effects of edaravone and flurbiprofen, administered alone and in combination, in a valproic acid (VPA)-induced autism model in male rats.
MATERIALS AND METHODS: An autism model was established through prenatal VPA exposure. Social behavior, anxiety, and memory were assessed using a battery of standardized behavioral tests. Pro-inflammatory and oxidative stress markers were evaluated via ELISA, and hippocampal neuronal density was assessed by Nissl staining.
RESULTS: All treatment groups (edaravone, flurbiprofen, and their combination) showed significant improvements in autism-related behaviors, including enhanced social interaction, reduced memory deficits, and decreased anxiety. The treatments lowered pro-inflammatory cytokines (IL-6, TNF-α) and MDA levels, while restoring the activity of antioxidant enzymes GPX and SOD.
CONCLUSIONS: Edaravone and flurbiprofen effectively improved autism-like behaviors by targeting shared pathways of oxidative stress and neuroinflammation. However, the combination therapy offered no additive benefits over monotherapy. This finding suggests that monotherapy with either drug is sufficient to achieve maximal therapeutic effects, a point with significant implications for future treatment strategies in ASD.
SIGNIFICANCE STATEMENT: This study advances neurodevelopmental neuroscience by demonstrating that independently targeting oxidative stress or neuroinflammation achieves maximal behavioral and hippocampal rescue in an autism model, revealing a convergent therapeutic ceiling that challenges combinatorial polypharmacy and refines our understanding of how overlapping pathological pathways govern neural circuit dysfunction and functional recovery.
MATERIALS AND METHODS: An autism model was established through prenatal VPA exposure. Social behavior, anxiety, and memory were assessed using a battery of standardized behavioral tests. Pro-inflammatory and oxidative stress markers were evaluated via ELISA, and hippocampal neuronal density was assessed by Nissl staining.
RESULTS: All treatment groups (edaravone, flurbiprofen, and their combination) showed significant improvements in autism-related behaviors, including enhanced social interaction, reduced memory deficits, and decreased anxiety. The treatments lowered pro-inflammatory cytokines (IL-6, TNF-α) and MDA levels, while restoring the activity of antioxidant enzymes GPX and SOD.
CONCLUSIONS: Edaravone and flurbiprofen effectively improved autism-like behaviors by targeting shared pathways of oxidative stress and neuroinflammation. However, the combination therapy offered no additive benefits over monotherapy. This finding suggests that monotherapy with either drug is sufficient to achieve maximal therapeutic effects, a point with significant implications for future treatment strategies in ASD.
SIGNIFICANCE STATEMENT: This study advances neurodevelopmental neuroscience by demonstrating that independently targeting oxidative stress or neuroinflammation achieves maximal behavioral and hippocampal rescue in an autism model, revealing a convergent therapeutic ceiling that challenges combinatorial polypharmacy and refines our understanding of how overlapping pathological pathways govern neural circuit dysfunction and functional recovery.